Announcement • Mar 16

CytomX Therapeutics, Inc. Announces Positive Data for Varsetatug Masetecan in Late-Line Colorectal Cancer

CytomX Therapeutics, Inc. announced positive Phase 1 expansion data for its EpCAM PROBODY ADC, varsetatug masetecan (Varseta-M) in late-line metastatic colorectal cancer. The preliminary data are as of a January 16, 2026 data cutoff from the ongoing CTMX-2051-101 Phase 1 study. Varsetatug Masetecan Phase 1 Expansion Data Summary in Advanced, Late-line Colorectal Cancer: The CTMX-2051-101 study was initiated in April 2024 with dose escalation proceeding through seven dose levels ranging from 2.4 mg/kg to 12 mg/kg. As of the data cutoff of January 16, 2026, a total of 93 patients with late-line metastatic CRC had been enrolled in the study. 60 patients were enrolled across the Phase 1 expansion dose range of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg of which 56 were efficacy evaluable as of the data cutoff. Starting in October 2025, the expansion doses of 8.6 mg/kg and 10 mg/kg were prioritized for dose optimization utilizing optimized adverse event management guidelines and adjusted ideal body weight (AIBW) dosing. 20 patients had been enrolled in expanded dose optimization as of the January 16 data cutoff towards an enrollment goal of 40 patients. Patient Characteristics: Patients enrolled in the study had previously received a median of 3 prior lines of therapy in the metastatic setting and 96% of patients had previously been treated with irinotecan. 76% of patients had liver metastases and 71% had KRAS mutations. Patients were not preselected based on EpCAM expression levels. All patients with evaluable tumor biopsies had high EpCAM levels as measured by immunohistochemistry. Efficacy: As of the data cutoff, 56 patients were efficacy-evaluable at the expansion doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W. Median duration of follow-up across the efficacy-evaluable patient population was approximately 8 months. Efficacy data across the Phase 1 Expansion doses are at the 8.6 mg/kg dose, the confirmed response rate was 20% with an estimated median PFS of 6.8 months and at the 10 mg/kg dose, the confirmed response rate was 32% with an estimated median PFS of 7.1 months. The disease control rate was 88% (49/56) across the expansion doses of 7.2 – 10 mg/kg. The doses of 8.6 mg/kg and 10 mg/kg have been prioritized for further evaluation with the goal of selecting a dose or doses for a registrational study. Dose optimization at 8.6 mg/kg and 10 mg/kg utilizing AIBW dosing and updated prophylaxis for adverse event management is ongoing. At the doses of 11 mg/kg Q3W and 12 mg/kg Q3W, which were not expanded for further evaluation, the overall response rate was 30% (3/10). Safety: As of the data cutoff, 93 patients were evaluable for safety including 80 patients across the expansion dose range of 7.2 mg/kg to 10 mg/kg. Varseta-M’s safety profile was generally consistent with data presented in Phase 1 dose escalation. Most treatment related adverse events were Grade 1 or Grade 2 in severity. No interstitial lung disease, febrile neutropenia or pancreatitis were observed. The most common treatment-related adverse event (TRAE) was diarrhea which was generally manageable and reversible. In Phase 1 dose expansions starting in second quarter of 2025, prophylactic strategies for diarrhea management were investigated. In dose optimization starting in fourth quarter of 2025, an updated prophylaxis regimen of anti-motility medication (loperamide or diphenoxylate/atropine) plus budesonide was implemented. In the 20 patients receiving the updated prophylactic regimen in dose optimization at doses of 8.6 mg/kg and 10 mg/kg, Grade 3 diarrhea was 10%. Overall, as of the January 16 2026 data cutoff, in the 80 patients treated at expansion and optimization doses ranging between 7.2 mg/kg to 10 mg/kg, the most common treatment-related adverse events (TRAEs) were diarrhea (68 pts, 19 Gr 3), nausea (44 pts, 4 Gr 3), vomiting (29 pts, 3 Gr 3), fatigue (32 pts, 2 Gr 3), hypokalemia (21 pts, 13 Gr 3+), and anemia (13 pts, 6 Gr 3). Serious treatment related adverse events (SAEs) in > 1 patient included diarrhea (4), vomiting (3), hypokalemia (3), dehydration (3), acute kidney injury (2), and colitis (2). As previously reported on August 13, 2025, there was one treatment-related grade 5 acute kidney injury (AKI) in a patient treated at the 7.2 mg/kg dose. The patient had a complex medical history including having a solitary kidney, and the AKI was determined to be secondary to Grade 3 nausea and Grade 2 diarrhea. No other Grade 5 TRAEs have been reported as of the January 16 2026 data cutoff. At the 11 mg/kg and 12 mg/kg doses, there were no dose limiting toxicities in dose escalation. The most common TRAEs across the patients in the 11 mg/kg dose (n=8) and 12 mg/kg dose (n=3) were diarrhea (9 pts, 6 GR 3), nausea, (8 pts, 0 Gr 3), and vomiting (8 pts, 1 Gr 3). Patients treated at the 11 and 12 mg/kg doses did not receive the optimized prophylactic regimen or adjusted ideal body weight dosing. Varsetatug Masetecan Next Steps: Additional efficacy and safety data from the Phase 1 study are expected to be presented at one or more medical meetings in 2026. The Company aims to align with the FDA in 2026 on a potential registrational study design for Varseta-M monotherapy in advanced CRC. A Phase 1 Varseta-M combination study with bevacizumab in CRC has been initiated and a Phase 1b/2 study in combination with bevacizumab and chemotherapy is expected to start by the end of 2026. Initiation of Phase 1 expansion cohort(s) in additional EpCAM-expressing indications is planned for second half of 2026.

Announcement • Feb 28

CytomX Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

On February 24, 2025, CytomX Therapeutics, Inc. received a written notice from the staff (the Staff") of the Listing Qualifications Department of the Nasdaq Stock Market (Nasdaq"), notifying the Company that, for the 30 consecutive business day period between January 8, 2025 and February 21, 2025 the Company's common stock, $0.00001 par value per share (the Common Stock"), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement"). The Notice has no immediate effect on the listing of the Company's common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule"), the Company has 180 calendar days, or until August 25, 2025 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price for the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to transfer its listing to the Nasdaq Capital Market and meet the continued listing requirement for the market value of publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to provide written notice to Nasdaq of its intention to cure the deficiency during the additional 180-day compliance period. As part of its review process, the Staff will make a determination of whether it believes the Company will be able to cure this deficiency. If it appears to the Staff that the Company will not be able to cure the deficiency or if the Company does not meet the other listing standards, then the Staff will provide written notice to the Company that its Common Stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Hearing Panel, such appeal would be successful. To address this issue, the Company intends to monitor the bid price of its Common Stock and take steps to increase the value of its Minimum Bid Price through implementation of its business strategy and consider its other options for regaining compliance with Minimum Bid Price Requirement.to monitor the However, the Company may not regain compliance with such requirement.

Total Shareholder Yield	-40.8%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Segment	Dividend Yield
Company (CTMX)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (CTMX) (up to 3 years)	n/a

Data	Last Updated (UTC time)
Company Analysis	2026/07/06 10:26
End of Day Share Price	2026/07/06 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Peter Lawson	Barclays
Etzer Darout	Barclays
Ying Huang	BofA Global Research

CytomX Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

CTMX: De Risked Epithelial Program And Pullback Will Support Future Repricing

CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations

CTMX: Late Line Colorectal Cancer Data Will Drive Bullish Repricing Prospects

CytomX Therapeutics: Cashed Up With Catalysts Ahead

Price target decreased by 10% to US$12.30

Cytomx Therapeutics, Inc. Appoints Mamata Gokhale as Senior Vice President of Regulatory Affairs

Consensus revenue estimates increase by 52%

Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher

Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics, Inc. to Report Q1, 2026 Results on May 07, 2026

CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects

CytomX Therapeutics, Inc., Annual General Meeting, Jun 17, 2026

CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path

CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis

Consensus revenue estimates fall by 29%

New major risk - Revenue and earnings growth

CytomX Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $249.999992 million.

Full year 2025 earnings: EPS and revenues miss analyst expectations

CytomX Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

New major risk - Share price stability

Investor sentiment improves as stock rises 34%

CytomX Therapeutics, Inc. Announces Positive Data for Varsetatug Masetecan in Late-Line Colorectal Cancer

CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis

CytomX Therapeutics, Inc. to Report Q4, 2025 Results on Mar 16, 2026

CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing

CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential

Insufficient new directors

What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You

CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing

Investor sentiment improves as stock rises 24%

CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program

CytomX Therapeutics, Inc. . Announces Clinical Program Updates and 2026 Milestones

CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline

CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential

Investor sentiment improves as stock rises 16%

CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer

Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically

Price target increased by 15% to US$7.07

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 10%

CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns

CytomX Therapeutics, Inc. to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting

Investor sentiment improves as stock rises 17%

CytomX Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target

Cytomx Therapeutics Appoints Rachael Lester as Senior Vice President, Chief Business Officer

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward

Investor sentiment improves as stock rises 25%

Investor sentiment deteriorates as stock falls 16%

Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%

CytomX Therapeutics, Inc. Provides Update on CX-2051 Phase 1 Study

Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks

Second quarter 2025 earnings released: US$0.001 loss per share (vs US$0.077 loss in 2Q 2024)

CytomX Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Chairman & CEO exercised options and sold US$149k worth of stock

Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching

Investor sentiment improves as stock rises 25%

Investor sentiment improves as stock rises 18%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story

CytomX Therapeutics, Inc. Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (Pembrolizumab) in Patients with Metastatic Melanoma

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target increased by 16% to US$5.50

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

CytomX Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.999999 million.

Investor sentiment improves as stock rises 44%

CytomX Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025

CytomX Therapeutics, Inc., Annual General Meeting, Jun 11, 2025

Consensus EPS estimates increase by 32%

Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive

Consensus revenue estimates increase by 26%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

CytomX Therapeutics, Inc. to Report Q4, 2024 Results on Mar 06, 2025